• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    DocGo Announces First Quarter 2025 Results

    5/8/25 4:05:00 PM ET
    $DCGO
    Medical/Nursing Services
    Health Care
    Get the next $DCGO alert in real time by email

    Company Focuses on Growing Medical Transportation and Payer & Provider Businesses, Navigates Municipal Uncertainty and Migrant Services Transition

    Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time

    DocGo Inc. (NASDAQ:DCGO) ("DocGo" or the "Company"), a leading provider of technology-enabled mobile health and medical transportation services, today announced financial and operating results for the quarter ended March 31, 2025.

    Lee Bienstock, Chief Executive Officer of DocGo, commented, "The impact of ongoing policy changes in Washington and adjustments to public spending on healthcare-related projects have created substantial uncertainty in our Government Population Health vertical at the federal, state and local levels. As a result, we have decided to remove all non-migrant Government Population Health revenue — and any related projections — from our 2025 guidance. I want to be clear, this revision is driven by our Government Population Health vertical. Our Hospital and Payer & Provider verticals continue to perform in line with expectations and we believe they are on a solid growth trajectory. During the quarter we completed a record number of medical transports along with several new contract wins and are experiencing care gap closure visit volumes that are approaching three times the amount we did this time last year." Bienstock concluded, "We believe our medical transportation and mobile health businesses hold tremendous promise and value for our company and for the healthcare system at large, and we look forward to their continued growth."

    2025 Guidance

    • Full-year 2025 revenue is expected to be $300-$330 million, compared to the previous estimate of $410-$450 million, due to the Company's decision to remove any non-migrant municipal population health revenue from its 2025 guidance. Revenue expectations from the Company's Medical Transportation and Payer & Provider businesses and remaining migrant services healthcare work are unchanged.
    • Full-year 2025 adjusted EBITDA1 is now expected to be a loss of $20-$30 million, compared to the previous expectation of a 5% adjusted EBITDA margin.1

    Norm Rosenberg, Chief Financial Officer of DocGo, also commented, "We plan to aggressively cut SG&A over the next several quarters, and anticipate positive cash flow through the balance of the year driven by collections of our outstanding migrant-related receivables. Additionally, we plan to utilize our strong balance sheet to take advantage of opportunities being presented by the current market uncertainty to grow both organically and through M&A."

    First Quarter 2025 Financial Highlights

    • Total revenue for the first quarter of 2025 was $96.0 million, compared to $192.1 million in the first quarter of 2024. The decline was due primarily to the planned wind-down of migrant-related programs.
    • GAAP gross margin (which includes depreciation and amortization expenses of $3.8 million) for the first quarter of 2025 was 28.2%, compared to 32.8% in the first quarter of 2024.
    • Adjusted gross margin2 for the first quarter of 2025 was 32.1%, compared to 35.0% in the first quarter of 2024.
    • Net loss for the first quarter of 2025 was $11.1 million, compared to net income of $10.6 million in the first quarter of 2024.
    • Adjusted EBITDA2 loss was $3.9 million for the first quarter of 2025, compared to adjusted EBITDA of $24.1 million for the first quarter of 2024.
    • Mobile Health Services revenue for the first quarter of 2025 was $45.2 million, compared to $143.9 million for the first quarter of 2024. The decline was due primarily to the wind-down of migrant-related programs.
    • Transportation Services revenue in the first quarter of 2025 was $50.8 million, compared to $48.2 million for the first quarter of 2024.
    • As of March 31, 2025, the Company held total cash and cash equivalents, including restricted cash, of approximately $103.1 million, compared to $107.3 million as of December 31, 2024.
    • During the first quarter of 2025, the Company repurchased 1.95 million shares of common stock for a total cost of approximately $5.8 million.
    • During the first quarter of 2025 the Company generated $9.7 million of cash flow from operations compared to cash used in operations of $10.6 million in the first quarter of 2024.

    Select Corporate Highlights for the First Quarter of 2025 and Recent Weeks

    • Signed a contract with a major New York health plan to offer DocGo Primary Care services to members who prefer the convenience of receiving healthcare in their home.
    • Surpassed 900,000 patients assigned by the Company's payer and provider partners for care gap closure services.
    • Signed a two-year contract with the North Texas division of a national health system to provide medical transportation services for their network of hospitals in Dallas and Fort Worth, TX.
    • Experienced a record quarter for the Company's medical transportation segment in terms of revenue and trip volume.
    • Signed a one-year contract that expands the Company's relationship with a California-based cardiology group and extends the Company's offering beyond CIED to provide virtual care management services for an additional 1,000 of their patients.
    • Continued enhancing the Company's tech stack with features that aim to improve transportation turnaround times and enable a 40% improvement in address search functionality for platform user requests.
    1. Adjusted EBITDA and adjusted EBITDA margin are non-GAAP financial measures. We have not reconciled adjusted EBITDA or adjusted EBITDA margin outlook to the most comparable GAAP outlooks because it is not possible to do so without unreasonable efforts due to the uncertainty and potential variability of reconciling items, which are dependent on future events and often outside of management's control and which could be significant. Because such items cannot be reasonably predicted with the level of precision required, we are unable to provide outlooks for the comparable GAAP measures (net income and net margin). Forward-looking estimates of adjusted EBITDA and adjusted EBITDA margin are made in a manner consistent with the relevant definitions and assumptions noted herein.



    2. Adjusted gross margin and adjusted EBITDA are non-GAAP financial measures. See "Non-GAAP Financial Measures" below for additional information on these non-GAAP financial measures and reconciliations to the most comparable GAAP measures.

    Conference Call and Webcast Details

    Thursday, May 8th, 2025 at 5:00 PM ET

    1-800-717-1738 - Investors Dial

    1-646-307-1865 - Int'l Investors Dial

    Conference ID: 65854

    Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1714626&tp_key=4f3bf2b60e

    The webcast can also be accessed under Events on the Investors section of the Company's website, https://ir.docgo.com/.

    About DocGo

    DocGo is leading the proactive healthcare revolution with an innovative care delivery platform that includes mobile health services, remote patient monitoring and ambulance services. DocGo is helping to reshape the traditional four-wall healthcare system by providing high quality, highly accessible care to patients where and when they need it. DocGo's proprietary technology and relationships with a dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for municipalities, hospital networks and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote advanced practice provider, in the comfort of a patient's home or workplace. Together with DocGo's integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com. To get an inside look on how the proactive healthcare revolution is helping transform healthcare by reducing costs, increasing efficiency and improving outcomes, visit www.proactivecarenow.com.

    Forward-Looking Statements

    This earnings release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the plans, strategies, outcomes, and prospects, both business and financial, of the Company, including the Company's expectations around the performance of each of its verticals; the impact of government policy changes; the Company's profitability and efforts to reduce SG&A as a percentage of revenues; cash flow and cash collections; the Company's cash balances; and the Company's future growth and M&A activity. These statements are based on the beliefs and assumptions of the Company's management. Although the Company believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, the Company cannot assure you that it will achieve or realize these plans, intentions, outcomes, results or expectations. Accordingly, you should not place undue reliance on such statements. All statements other than statements of historical fact are forward-looking, including, but not limited, to statements regarding the Company's future actions, business strategies or models, plans, goals, future events, future revenues, future margins, current and future revenue guidance, future growth or performance, financing needs, business trends, results of operations, objectives and intentions with respect to future operations, services and products, and new and existing contracts or partnerships. In some cases, these statements may be preceded by, followed by or include the words "believes," "estimates," "expects," "projects," "forecasts," "may," "might," "will," "should," "could," "can," "would," "design," "potential," "seeks," "plans," "scheduled," "anticipates," "intends" or the negative of these terms or similar expressions.

    Forward-looking statements are inherently subject to substantial risks, uncertainties and assumptions, many of which are beyond the Company's control, and which may cause its actual results or outcomes, or the timing of its results or outcomes, to differ materially from those contained in its forward-looking statements, including, but not limited to the following: impacts related to accelerated wind down of migrant-related services; uncertainties related to future non-migrant municipal population health revenue; the Company's ability to return to profitability and/or expand its programs with insurance partners, hospital systems, municipalities and other strategic partners; the Company's ability to successfully implement its business strategy, including delivering value to shareholders via buybacks, funding new strategic relationships and potentially repaying its line of credit; the Company's ability to establish, maintain and grow customer relationships; the Company's ability to execute projects to the satisfaction of its customers; the Company's ability to grow demand for its care gap closure programs; the Company's ability to maintain or grow its cash balances; the Company's reliance on and ability to maintain its contractual relationships with its healthcare provider partners and other strategic partners; the Company's ability to compete effectively in a highly competitive industry, including conditions in the healthcare transportation and mobile health services markets; the Company's ability to maintain existing contracts; the Company's reliance on government contracts, including changes in government spending on healthcare and other social services; recent revenue growth derived from a small number of large customers; the Company's ability to effectively manage its growth; the Company's financial performance and future prospects; the Company's ability to deliver on its business strategies or models, plans and goals; the Company's ability to expand geographically; the Company's M&A activity and success of its acquisition strategy; the Company's ability to retain its workforce and management personnel and successfully manage leadership transitions; the availability of healthcare professionals and other personnel; changes in the cost of labor; the Company's ability to collect on customer receivables; risks associated with the Company's share repurchase program; overall macroeconomic and geopolitical conditions, including the interest rate environment, the inflationary environment, the potential recessionary environment, regional conflict and tensions, financial institution instability and the prospect of a shutdown of the U.S. federal government; the ability of the Company's suppliers to meet its needs; the Company's ability to obtain or maintain operating licenses; potential changes in federal, state or local government policies or priorities; expected impacts of geopolitical instability; the Company's competitive position and opportunities, including its ability to realize the benefits from its operating model; the Company's ability to improve gross margins; the Company's ability to implement and deliver on cost-containment measures and ongoing cost rationalization initiatives; legislative and regulatory actions; the impact of legal proceedings and compliance risk; volatility of our stock price; the impact on the Company's business and reputation in the event of information technology system failures, network disruptions, cyber incidents or losses or unauthorized access to, or release of, confidential information; the Company's ability to comply with laws and regulations regarding data privacy and protection and other risk factors included in the Company's filings with the Securities and Exchange Commission ("SEC").

    Moreover, the Company operates in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for the Company to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this earnings release. The results, events, and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results or outcomes could differ materially from those described in the forward-looking statements.

    The forward-looking statements made in this earnings release are based on events or circumstances as of the date on which the statements are made. The Company undertakes no obligation to update any forward-looking statements made in this earnings release to reflect events or circumstances after the date of this earnings release or to reflect new information or the occurrence of unanticipated events, except as and to the extent required by law. The Company's forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments.

    DocGo Inc. and Subsidiaries

     

    UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

    March 31,

    2025
    December 31,

    2024
    Unaudited Audited
    ASSETS
    Current assets:
    Cash and cash equivalents

    $

    79,007,535

     

    $

    89,241,695

     

    Accounts receivable, net of allowance for credit loss of $5,782,232 and $5,873,942 as of March 31, 2025 and December 31, 2024, respectively

     

    178,755,898

     

     

    210,899,926

     

    Prepaid expenses and other current assets

     

    4,767,998

     

     

    4,344,642

     

    Total current assets

     

    262,531,431

     

     

    304,486,263

     

    Property and equipment, net

     

    15,049,767

     

     

    14,881,411

     

    Intangibles, net

     

    27,343,578

     

     

    25,728,813

     

    Goodwill

     

    49,554,226

     

     

    47,432,550

     

    Restricted cash

     

    24,051,509

     

     

    18,095,612

     

    Operating lease right-of-use assets

     

    13,665,630

     

     

    11,958,698

     

    Finance lease right-of-use assets

     

    17,159,190

     

     

    15,337,299

     

    Investments

     

    5,507,281

     

     

    5,547,979

     

    Deferred tax assets

     

    12,349,462

     

     

    8,422,034

     

    Other assets

     

    3,580,924

     

     

    3,730,473

     

    Total assets

    $

    430,792,998

     

    $

    455,621,132

     

    LIABILITIES AND STOCKHOLDERS' EQUITY
    Current liabilities:
    Accounts payable

    $

    20,518,829

     

    $

    28,356,430

     

    Accrued liabilities

     

    41,406,981

     

     

    49,896,796

     

    Line of credit

     

    30,000,000

     

     

    30,000,000

     

    Notes payable, current

     

    12,931

     

     

    12,515

     

    Due to seller

     

    1,138,075

     

     

    28,656

     

    Contingent consideration

     

    4,947,614

     

     

    4,973,152

     

    Operating lease liability, current

     

    4,447,517

     

     

    3,844,561

     

    Finance lease liability, current

     

    5,099,151

     

     

    4,694,467

     

    Total current liabilities

     

    107,571,098

     

     

    121,806,577

     

    Notes payable, non-current

     

    2,155

     

     

    5,215

     

    Operating lease liability, non-current

     

    9,898,110

     

     

    8,599,072

     

    Finance lease liability, non-current

     

    11,396,832

     

     

    10,031,138

     

    Total liabilities

     

    128,868,195

     

     

    140,442,002

     

    Commitments and contingencies
    Stockholders' equity:
    Common stock ($0.0001 par value; 500,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 100,183,888 and 101,910,883 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively)

     

    10,018

     

     

    10,191

     

    Additional paid-in-capital

     

    318,417,191

     

     

    321,087,583

     

    Accumulated deficit

     

    (10,807,482

    )

     

    (1,402,167

    )

    Accumulated other comprehensive income

     

    1,717,407

     

     

    1,221,869

     

    Total stockholders' equity attributable to DocGo Inc. and Subsidiaries

     

    309,337,134

     

     

    320,917,476

     

    Noncontrolling interests

     

    (7,412,331

    )

     

    (5,738,346

    )

    Total stockholders' equity

     

    301,924,803

     

     

    315,179,130

     

    Total liabilities and stockholders' equity

    $

    430,792,998

     

    $

    455,621,132

     

    DocGo Inc. and Subsidiaries

     

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME

     
     
    Three Months Ended

    March 31,

     

    2025

     

     

    2024

     

    Revenues, net

    $

    96,033,055

     

    $

    192,087,529

     

    Expenses:
    Cost of revenues (exclusive of depreciation and amortization, which is shown separately below)

     

    65,185,060

     

     

    124,808,914

     

    Operating expenses:
    General and administrative

     

    32,902,070

     

     

    40,181,035

     

    Depreciation and amortization

     

    3,761,391

     

     

    4,182,781

     

    Legal and regulatory

     

    4,210,823

     

     

    4,313,503

     

    Technology and development

     

    3,639,444

     

     

    2,388,919

     

    Sales, advertising and marketing

     

    331,705

     

     

    337,010

     

    Total expenses

     

    110,030,493

     

     

    176,212,162

     

    (Loss) income from operations

     

    (13,997,438

    )

     

    15,875,367

     

    Other expense:
    Interest (expense), net

     

    (426,284

    )

     

    (369,008

    )

    Change in fair value of contingent liability

     

    —

     

     

    6,446

     

    (Loss) on equity method investments

     

    (40,698

    )

     

    (83,167

    )

    (Loss) on remeasurement of operating and finance leases

     

    (40,837

    )

     

    (4,697

    )

    Gain on disposal of fixed assets

     

    15,139

     

     

    52,835

     

    Other (expense) income

     

    (312,869

    )

     

    244,607

     

    Total other (expense)

     

    (805,549

    )

     

    (152,984

    )

    Net (loss) income before income tax (expense) benefit

     

    (14,802,987

    )

     

    15,722,383

     

    Benefit from (provision for) income taxes

     

    3,723,687

     

     

    (5,119,004

    )

    Net (loss) income

     

    (11,079,300

    )

     

    10,603,379

     

    Net loss attributable to noncontrolling interests

     

    (1,673,985

    )

     

    (624,070

    )

    Net (loss) income attributable to stockholders of DocGo Inc. and Subsidiaries

     

    (9,405,315

    )

     

    11,227,449

     

    Other comprehensive income
    Foreign currency translation adjustment

     

    495,538

     

     

    (140,134

    )

    Total comprehensive (loss) income

    $

    (8,909,777

    )

    $

    11,087,315

     

    Net (loss) income per share attributable to DocGo Inc. and Subsidiaries - Basic

    $

    (0.09

    )

    $

    0.11

     

    Weighted-average shares outstanding - Basic

     

    101,594,579

     

     

    103,818,362

     

    Net (loss) income per share attributable to DocGo Inc. and Subsidiaries - Diluted

    $

    (0.09

    )

    $

    0.10

     

    Weighted-average shares outstanding - Diluted

     

    101,594,579

     

     

    108,506,435

     

     

    DocGo Inc. and Subsidiaries

     

     

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

     
    Three Months Ended

    March 31,

     

    2025

     

     

    2024

     

    CASH FLOWS FROM OPERATING ACTIVITIES:
    Net (loss) income

    $

    (11,079,300

    )

    $

    10,603,379

     

    Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:
    Depreciation of property and equipment

     

    1,220,806

     

     

    1,431,308

     

    Amortization of intangible assets

     

    1,299,142

     

     

    1,694,983

     

    Amortization of finance lease right-of-use assets

     

    1,241,443

     

     

    1,056,490

     

    Gain on disposal of fixed assets

     

    (15,139

    )

     

    (52,835

    )

    Deferred income tax

     

    (3,927,428

    )

     

    (55,776

    )

    Loss on equity method investments

     

    40,698

     

     

    83,167

     

    Bad debt expense

     

    1,247,991

     

     

    1,357,621

     

    Stock-based compensation

     

    4,830,312

     

     

    3,988,339

     

    Loss on remeasurement of operating and finance leases

     

    40,837

     

     

    4,697

     

    Change in fair value of contingent consideration

     

    —

     

     

    (6,446

    )

    Changes in operating assets and liabilities:
    Accounts receivable

     

    31,437,734

     

     

    (22,401,596

    )

    Prepaid expenses and other current assets

     

    (386,734

    )

     

    6,728,337

     

    Other assets

     

    538,190

     

     

    (62,016

    )

    Accounts payable

     

    (7,684,101

    )

     

    5,800,891

     

    Accrued liabilities

     

    (9,148,984

    )

     

    (20,810,287

    )

    Net cash provided by (used in) operating activities

     

    9,655,467

     

     

    (10,639,744

    )

     
    CASH FLOWS FROM INVESTING ACTIVITIES:
    Acquisition of property and equipment

     

    (1,468,364

    )

     

    (951,702

    )

    Acquisition of intangibles

     

    (712,711

    )

     

    (773,039

    )

    Acquisition of a business

     

    (3,646,318

    )

     

    —

     

    Proceeds from disposal of property and equipment

     

    94,341

     

     

    25,000

     

    Net cash used in investing activities

     

    (5,733,052

    )

     

    (1,699,741

    )

     
    CASH FLOWS FROM FINANCING ACTIVITIES:
    Proceeds from revolving credit line

     

    —

     

     

    45,000,000

     

    Repayments of revolving credit line

     

    —

     

     

    (40,000,000

    )

    Repayments of notes payable

     

    (3,060

    )

     

    (9,624

    )

    Due to seller

     

    —

     

     

    (3,862

    )

    Earnout payments on contingent liabilities

     

    (265,538

    )

     

    —

     

    Payments for taxes related to shares withheld for employee taxes

     

    (1,200,977

    )

     

    (20,946

    )

    Common stock repurchased

     

    (5,751,954

    )

     

    (4,877,559

    )

    Payments on obligations under finance lease

     

    (1,296,887

    )

     

    (969,588

    )

    Net cash used in financing activities

     

    (8,518,416

    )

     

    (881,579

    )

     
    Effect of exchange rate changes on cash and cash equivalents

     

    317,738

     

     

    (103,059

    )

     
    Net decrease in cash and restricted cash

     

    (4,278,263

    )

     

    (13,324,123

    )

    Cash and restricted cash at beginning of period

     

    107,337,307

     

     

    72,217,986

     

    Cash and restricted cash at end of period

    $

    103,059,044

     

    $

    58,893,863

     

     
     
    Three Months Ended

    March 31,

     

    2025

     

     

    2024

     

    Supplemental disclosure of cash and non-cash transactions:
    Cash paid for interest

    $

    561,707

     

    $

    448,057

     

    Cash paid for interest on finance lease liabilities

    $

    220,055

     

    $

    181,883

     

    Cash paid for income taxes

    $

    1,906,712

     

    $

    557,598

     

    Right-of-use assets obtained in exchange for lease liabilities

    $

    5,966,095

     

    $

    2,791,964

     

    Remeasurement of finance lease right-of-use asset due to lease modification

    $

    —

     

    $

    300,000

     

     
    Reconciliation of cash and restricted cash
    Cash

    $

    79,007,535

     

    $

    41,244,446

     

    Restricted cash

     

    24,051,509

     

     

    17,649,417

     

    Total cash and restricted cash shown in statement of cash flows

    $

    103,059,044

     

    $

    58,893,863

     

    Non-GAAP Financial Measures

    The following information provides definitions and reconciliation of non-GAAP financial measures used by the Company to the most directly comparable financial measures calculated and presented in accordance with generally accepted accounting principles ("GAAP"). The Company has provided this non-GAAP financial information, which is not calculated or presented in accordance with GAAP, as information supplemental and in addition to the financial measures presented in this earnings release that are calculated and presented in accordance with GAAP. Such non-GAAP financial measures should not be considered superior to, as a substitute for or alternative to, and should be considered in conjunction with, the GAAP financial measures presented in this earnings release. The non-GAAP financial measures used by the Company may differ from similarly titled measures used by other companies.

    Adjusted Gross Margin

    Adjusted gross profit and adjusted gross margin are considered non-GAAP financial measures under SEC rules because they exclude certain amounts included in gross profit and gross margin calculated in accordance with GAAP. Adjusted gross profit is total revenue minus cost of revenue, excluding depreciation and amortization (which are shown separately), and adjusted gross margin is adjusted gross profit as a percentage of total revenue.

    The Company's management believes that adjusted gross margin is useful in evaluating DocGo's operating performance, as the calculation of this measure excludes the impact of non-cash depreciation and amortization charges. The Company's management believes that by using adjusted gross margin in conjunction with GAAP gross margin, investors will get a more complete view of what management considers to be the Company's core operating performance and allow for comparison of this measure when compared to those of prior periods. While many companies use adjusted gross margin as a performance measure, not all companies use identical calculations for determining adjusted gross margin. As such, DocGo's presentation of adjusted gross margin might not be comparable to similarly titled measures of other companies.

    Adjusted EBITDA

    Adjusted EBITDA is considered a non-GAAP financial measure under SEC rules because it excludes certain amounts included in net income (loss) calculated in accordance with GAAP. Specifically, adjusted EBITDA is arrived at by taking reported GAAP net income and adding back the following items: net interest expense (income), provision for (benefit from) income taxes, depreciation and amortization, other (income) expense, non-cash equity-based compensation and certain other non-recurring expenses consisting of certain one-time legal settlements and certain one-time expenses incurred in connection with acquisitions and other corporate activities, beyond those that are typically incurred.

    The Company's management believes that its adjusted EBITDA measure is useful in evaluating DocGo's operating performance, as the calculation of this measure generally eliminates the effect of financing and income taxes and the accounting effects of capital spending and acquisitions, as well as other items of a non-recurring and/or non-cash nature. Adjusted EBITDA is not intended to be a measure of GAAP cash flow, as this measure does not consider certain cash-based expenses, such as payments for taxes or debt service.

    Management believes that using adjusted EBITDA in conjunction with GAAP measures such as net income assists investors in getting a more complete picture of the Company's financial results and operations, affording them with a more complete view of what management considers to be the Company's core operating performance as well as offering the ability to assess such performance as compared with that of prior periods and management's public guidance. While many companies use adjusted EBITDA as a performance measure, not all companies use identical calculations for determining adjusted EBITDA. As such, DocGo's presentation of adjusted EBITDA might not be comparable to similarly titled measures of other companies.

    Adjusted EBITDA Margin

    Adjusted EBITDA margin is considered a non-GAAP measure under SEC rules. It is calculated by dividing adjusted EBITDA by revenues. Management believes using adjusted EBITDA margin in conjunction with GAAP measures, such as gross margin and/or net margin, is useful to investors because it assists investors in getting a more complete view of what management considers the Company's core operating performance, as expressed in marginal terms. While many companies use adjusted EBITDA margin as a performance measure, not all companies use identical calculations for determining adjusted EBITDA margin. As such, DocGo's presentation of adjusted EBITDA margin might not be comparable to similarly titled measures of other companies.

    Reconciliation of Non-GAAP Measures

    The table below reflects the reconciliation of GAAP gross margin and adjusted gross margin for the three months ended March 31, 2025 compared to the same period in 2024:

     
    Three Months Ended

    March 31,

    2025

    2024

    Revenue

    $96,033,055

    $192,087,529

    Cost of revenue (exclusive of depreciation and amortization, which are shown separately below)

    (65,185,060)

    (124,808,914)

    Depreciation and amortization

    (3,761,391)

    (4,182,781)

    GAAP gross profit

    27,086,604

    63,095,834

     

     

    Depreciation and amortization

    3,761,391

    4,182,781

    Adjusted gross profit

    30,847,995

    67,278,615

     

     

    GAAP gross margin

    28.2%

    32.8%

    Adjusted gross margin

    32.1%

    35.0%

    The table below reflects the reconciliation of net income (loss) to adjusted EBITDA for the three months ended March 31, 2025 compared to the same period in 2024 (in millions):

     
    Three Months Ended

    March 31,

    2025

    2024

    Net income (GAAP)

    ($11.1)

    $10.6

    (+) Net interest expense

    $0.4

    $0.4

    (+) Income tax

    ($3.7)

    $5.1

    (+) Depreciation and amortization

    $3.8

    $4.2

    (+) Other (income) expense

    $0.4

    ($0.2)

    EBITDA

    ($10.2)

    $20.1

     

     

    (+) Non-cash stock compensation

    $4.8

    $4.0

    (+) Non-recurring expense

    $1.5

    $0.0

     

     

    Adjusted EBITDA

    ($3.9)

    $24.1

     

     

    Total revenue

    $96.0

    $192.1

    Pretax income margin

    -15.4%

    8.2%

    Net margin

    -11.6%

    5.5%

    Adjusted EBITDA margin

    -4.1%

    12.5%

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250508310873/en/

    Investors:

    Mike Cole

    DocGo

    949-444-1341

    [email protected]

    [email protected]

    Get the next $DCGO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DCGO

    DatePrice TargetRatingAnalyst
    5/9/2025Buy → Neutral
    BTIG Research
    2/28/2025$5.00 → $2.85Buy → Hold
    Deutsche Bank
    8/18/2023$15.00Buy
    BTIG Research
    4/21/2023$11.00Overweight
    Cantor Fitzgerald
    4/19/2022$11.00Buy
    Deutsche Bank
    1/19/2022$14.00Buy
    Stifel
    12/21/2021$13.00Buy
    Canaccord Genuity
    12/7/2021$14.00Buy
    Needham
    More analyst ratings

    $DCGO
    Leadership Updates

    Live Leadership Updates

    See more
    • DocGo Acquires PTI Health To Expand Proactive Healthcare Offering with Mobile Lab Collection and Mobile Phlebotomy Services

      DocGo Inc. (NASDAQ:DCGO) ("DocGo" or the "Company"), a leading provider of technology-enabled mobile health services, today announced the acquisition of PTI Health, a mid-Atlantic mobile lab collection and phlebotomy services company. This strategic move expands DocGo's healthcare service offering to include mobile phlebotomy lab services, addressing critical gaps in diagnostic care for underserved populations. With this acquisition, DocGo will facilitate timely, convenient blood collection and additional at-home testing services for patients, offering a new level of care to those with limited access to traditional labs or transportation options. The acquisition enhances DocGo's offerings

      2/10/25 7:35:00 AM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • DocGo Appoints Healthcare Visionary Dr. Stephen K. Klasko as Chair of the Board

      DocGo Inc. (NASDAQ:DCGO) ("DocGo" or the "Company"), a leading provider of technology-enabled mobile health services, today announced the appointment of Stephen K. Klasko, M.D., M.B.A as the new independent, non-executive Chair of its Board of Directors, effective October 1, 2024. Dr. Klasko has an extensive background in leadership roles within healthcare, higher education and medical industry innovation, including an eight-year tenure as the President of Thomas Jefferson University and the CEO of Jefferson Health where he oversaw its expansion to 18 hospitals and over 35,000 employees. Prior to that, he was CEO of USF Health and Dean of the Morsani College of Medicine at the University o

      9/30/24 7:35:00 AM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • DocGo Appoints Eiwe Lingefors as New Chief Information Officer

      DocGo Inc. (NASDAQ:DCGO) ("DocGo" or the "Company"), a leading provider of technology-driven healthcare solutions, is proud to announce Eiwe Lingefors as Chief Information Officer (CIO). Lingefors most recently served as the company's Chief Information Security Officer, and will continue in this role as well. In his new role as CIO, Lingefors will lead both DocGo's information security and digital innovation strategy in an evolving cybersecurity landscape. "Eiwe has been a vital part of our team, and his deep expertise in the security landscape has been instrumental in DocGo's operations," said Lee Bienstock, CEO of DocGo. "He has done an excellent job strengthening DocGo's existing cybers

      9/26/24 7:35:00 AM ET
      $DCGO
      Medical/Nursing Services
      Health Care

    $DCGO
    SEC Filings

    See more
    • SEC Form 10-Q filed by DocGo Inc.

      10-Q - DocGo Inc. (0001822359) (Filer)

      5/8/25 4:35:04 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • DocGo Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - DocGo Inc. (0001822359) (Filer)

      5/8/25 4:15:49 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • SEC Form SCHEDULE 13G filed by DocGo Inc.

      SCHEDULE 13G - DocGo Inc. (0001822359) (Subject)

      4/30/25 10:53:25 AM ET
      $DCGO
      Medical/Nursing Services
      Health Care

    $DCGO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DocGo Announces First Quarter 2025 Results

      Company Focuses on Growing Medical Transportation and Payer & Provider Businesses, Navigates Municipal Uncertainty and Migrant Services Transition Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time DocGo Inc. (NASDAQ:DCGO) ("DocGo" or the "Company"), a leading provider of technology-enabled mobile health and medical transportation services, today announced financial and operating results for the quarter ended March 31, 2025. Lee Bienstock, Chief Executive Officer of DocGo, commented, "The impact of ongoing policy changes in Washington and adjustments to public spending on healthcare-related projects have created substantial uncertainty in our Government Populati

      5/8/25 4:05:00 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • DocGo to Announce First Quarter Results on Thursday, May 8, 2025

      Management to host conference call and webcast at 5:00 p.m. ET on that day DocGo Inc. (NASDAQ:DCGO) ("DocGo" or the "Company"), a leading provider of technology-enabled mobile health services, announced today that the Company will release its financial results for the first quarter ended March 31st, 2025 after the markets close on Thursday, May 8th, 2025. Management will also host a conference call to discuss these results at 5:00 p.m. ET on that day. Conference call and webcast details: Thursday, May 8th, 2025 5:00 p.m. ET 1-800-717-1738 (U.S.) 1-646-307-1865 (international) Conference ID: 65854 To access the Call me™ feature, which avoids the need to wait for an operator, click https:

      4/21/25 7:35:00 AM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • DocGo Earns Great Place To Work Certification™ For the Third Time in a Row

      DocGo Inc. (NASDAQ:DCGO) ("DocGo" or the "Company"), a leading provider of technology-enabled mobile health services, today announced that it has been Certified™ by Great Place To Work® for the third time in a row. This prestigious award is based on what current employees say about their experience working at the Company. This year, employees rated DocGo 31% higher than the average US company as a Great Place to Work. Great Place To Work® is the global authority on workplace culture, employee experience and the leadership behaviors proven to deliver market-leading revenue, employee retention and increased innovation. "Our clinicians who bring care to patients where they need it – and the

      3/31/25 7:35:00 AM ET
      $DCGO
      Medical/Nursing Services
      Health Care

    $DCGO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $DCGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $DCGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $DCGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $DCGO
    Financials

    Live finance-specific insights

    See more
    • Burdiek Michael J bought $34,000 worth of shares (10,000 units at $3.40), increasing direct ownership by 2% to 581,595 units (SEC Form 4)

      4 - DocGo Inc. (0001822359) (Issuer)

      5/14/24 4:10:44 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • Tendler Ely D bought $31,300 worth of shares (10,000 units at $3.13), increasing direct ownership by 7% to 162,933 units (SEC Form 4)

      4 - DocGo Inc. (0001822359) (Issuer)

      5/13/24 4:34:19 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • Bienstock Lee bought $78,750 worth of shares (25,000 units at $3.15), increasing direct ownership by 2% to 1,220,845 units (SEC Form 4)

      4 - DocGo Inc. (0001822359) (Issuer)

      5/13/24 4:30:30 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • Chief Compliance Officer Sugrue Stephen covered exercise/tax liability with 5,614 shares, decreasing direct ownership by 2% to 347,328 units (SEC Form 4)

      4 - DocGo Inc. (0001822359) (Issuer)

      4/2/25 4:45:15 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • CFO and Treasurer Rosenberg Norman covered exercise/tax liability with 8,004 shares, decreasing direct ownership by 0.93% to 856,272 units (SEC Form 4)

      4 - DocGo Inc. (0001822359) (Issuer)

      4/2/25 4:44:31 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • Chief Executive Officer Bienstock Lee covered exercise/tax liability with 37,340 shares, decreasing direct ownership by 2% to 1,956,079 units (SEC Form 4)

      4 - DocGo Inc. (0001822359) (Issuer)

      4/2/25 4:43:52 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • Amendment: SEC Form SC 13D/A filed by DocGo Inc.

      SC 13D/A - DocGo Inc. (0001822359) (Subject)

      11/29/24 4:14:57 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by DocGo Inc.

      SC 13G/A - DocGo Inc. (0001822359) (Subject)

      11/14/24 9:56:36 AM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G/A filed by DocGo Inc. (Amendment)

      SC 13G/A - DocGo Inc. (0001822359) (Subject)

      3/1/24 4:53:15 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • DocGo downgraded by BTIG Research

      BTIG Research downgraded DocGo from Buy to Neutral

      5/9/25 8:41:42 AM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • DocGo downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded DocGo from Buy to Hold and set a new price target of $2.85 from $5.00 previously

      2/28/25 8:51:46 AM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • BTIG Research initiated coverage on DocGo with a new price target

      BTIG Research initiated coverage of DocGo with a rating of Buy and set a new price target of $15.00

      8/18/23 7:24:03 AM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • DocGo Announces First Quarter 2025 Results

      Company Focuses on Growing Medical Transportation and Payer & Provider Businesses, Navigates Municipal Uncertainty and Migrant Services Transition Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time DocGo Inc. (NASDAQ:DCGO) ("DocGo" or the "Company"), a leading provider of technology-enabled mobile health and medical transportation services, today announced financial and operating results for the quarter ended March 31, 2025. Lee Bienstock, Chief Executive Officer of DocGo, commented, "The impact of ongoing policy changes in Washington and adjustments to public spending on healthcare-related projects have created substantial uncertainty in our Government Populati

      5/8/25 4:05:00 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • DocGo to Announce First Quarter Results on Thursday, May 8, 2025

      Management to host conference call and webcast at 5:00 p.m. ET on that day DocGo Inc. (NASDAQ:DCGO) ("DocGo" or the "Company"), a leading provider of technology-enabled mobile health services, announced today that the Company will release its financial results for the first quarter ended March 31st, 2025 after the markets close on Thursday, May 8th, 2025. Management will also host a conference call to discuss these results at 5:00 p.m. ET on that day. Conference call and webcast details: Thursday, May 8th, 2025 5:00 p.m. ET 1-800-717-1738 (U.S.) 1-646-307-1865 (international) Conference ID: 65854 To access the Call me™ feature, which avoids the need to wait for an operator, click https:

      4/21/25 7:35:00 AM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • DocGo Announces Fourth Quarter and Full-Year 2024 Results

      Company Surpasses 700,000 Total Patient Lives Assigned for Care Gap Closure Programs and Expands Contracts With Payer Partners on Both Coasts Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time DocGo Inc. (NASDAQ:DCGO) ("DocGo" or the "Company"), a leading provider of technology-enabled mobile health services, today announced financial and operating results for the quarter and full-year ended December 31, 2024. Full-Year 2024 Financial Highlights Full-year 2024 revenue was $616.6 million, compared to $624.2 million for the full-year 2023. GAAP gross margin (which includes non-cash depreciation expenses) for the full-year 2024 was 32.1%, compared to 28.7%

      2/27/25 4:11:00 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care